Immunologic Endpoints Against Young Infant Group B Streptococcal Disease

1029
infectious disease
Immunologic Endpoints Against Young Infant Group B Streptococcal Disease
United States of America
To provide a case-control study comparing naturally occurring group B strep antibodies in young infants with invasive disease versus controls will establish antibody thresholds associated with protection and inform decisions about future maternal Group B Streptococcus vaccine licensure.

World Meningitis Day 2018: Eliminating Epidemics of Meningococcal A Meningitis

Read more

From Food Safety to Flu, CDC Protects the Health of Your Business

Read more

Pneumococcal Disease in Qatar

789
pneumoccal
Pneumococcal Disease in Qatar
Qatar
To evaluate the impact of Pneumococcal Conjugate Vaccine (PCV-13) on vaccine and non-vaccine serotypes causing both invasive and non-invasive diseases in Qatar. The study also assesses the overall prevalence and serotype distribution of S.pneumoniae nasopharyngeal carriage in both healthy and sick children below five years of age over a three-year period.
Hamad Medical Corporation
CDC's National Center for Immunization and Respiratory Diseases


CDC: Working to Stop the Cough Heard Around the World

Read more
Subscribe to Bacterial Diseases